

ISHEN 2017
Day 1 [Pathogenesis]; March 9, 2017

Day 1: Pathogenesis

8:00-8:15 Welcome notes

8:15-10:00 Hepatic Encephalopathy: What are the main challenges?

Learning Objective: To review current knowledge and future challenges

Chairs: Radha K. Dhiman and Sara Montagnese

	Title of the Talk	Speaker	Institution
8:15-8:45	Pathogenesis	Christopher Rose	
8:45-9:15	Diagnosis and classification	Piero Amodio	
9:15-9:45	Treatment	Rajiv Jalan	
9:45-10:00	Discussion		

10:00-10:30 Refreshment Break

10:30-12:30 **SESSION 1: PATHOGENESIS – 1 (BRAIN EDEMA)**

Learning Objective: To understand the role of brain edema in HE, what causes brain edema, intracranial hypertension and the role of the blood brain barrier

Chairs: Peter Ott and Sunil Taneja

Speakers

	Title of the Talk	Speaker	Institution
10:30-10:50	Neurochemistry of hepatic encephalopathy	Alexander Gourine	
10:50-11:10	Blood brain barrier in HE	Nicolaas Weiss	
11:10-11:30	Cause or effect of HE	Cristina Romana Cudalbu	
11:30-11:45	Young Investigator selected from the submitted abstracts	To be selected	
11:45-12:00	Young Investigator selected from the submitted abstracts	To be selected	
12:00-12:30	Discussion		

12:30-13:30 **Lunch**

13:30-15:30 **SESSION 2: PATHOGENESIS- 2**

Learning Objective: It will comprise a series of talks by established ISHEN members to establish the basic understanding of the key science areas related to pathogenesis of hepatic encephalopathy.

Chairs: **Dieter Haussinger and Shiv Sarin**

Speakers

Time	Title of the Talk	Speaker	Institution
13:30-13:50	Ammonia and neurotoxicity	Mike Norenberg	
13:50-14:10	Neuronal cell loss in HE	Roger Butterworth	
14:10-14:30	Inflammation	Mark Swain	
14:30-14:45	Young Investigator selected from the submitted abstracts	To be selected	
14:45-15:00	Young Investigator selected from the submitted abstracts	To be selected	
15:00-15:15	Discussion		

15:15-15:45 **Tea break**

15:45-17:45 **SESSION 3: PATHOGENESIS – 3**

Learning Objective: It will comprise a series of talks by established ISHEN members to establish the basic understanding of the key science areas related to pathogenesis of hepatic encephalopathy.

Chairs: **AR Jayakumar and Nathan Davies**

Speakers

Time	Title of the Talk	Speaker	Institution
15:45-16:00	Cerebral blood flow and brain bioenergetics	Peter Bjerring	
16:00-16:15	Molecular and cellular basis	Andre Quincozes-Santos	
16:15-16:30	Role of Bile acids	Sharon De Morrow	
16:30-16:45	Ammonia and senescence	Boris Görg	
16:45-17:00	Young Investigator selected from the submitted abstracts	To be selected	
17:00-17:15	Young Investigator selected from the submitted abstracts	To be selected	
17:15-17:30	Discussion		

17:30-18:00 **Andy Blei Lecture: Dieter Häussinger**

18:00-19:30 **Poster sessions with wine and Indian traditional snacks**

19:30

Dinner

ISHEN 2016
Day 2 [Diagnosis]March 10, 2017

08:00-10:00

SESSION 4: WORKSHOP 1 (CLINICAL): MINIMAL/COVERT HEPATIC ENCEPHALOPATHY

Learning Objective: The diagnosis and manage of minimal/covert HE is one of the most contentious issues in the area of hepatic encephalopathy. Following issues will be discussed

Chairs: Vishal Patel and Karin Weissenborn

Speakers:

	Title of the Talk	Speaker	Institution
8:00-8:10	Who is normal (Normal mental state)	Sara Montagnese	
8:10-8:20	Is it rational to combine MHE and Grade 1	Jasmohan Bajaj	
8:20-8:30	Who should be tested?	Marsha Morgan	
8:30-8:40	MHE testing in real world scenario	Mette Lauridsen	
8:40-8:50	Prospective large scale MHE validation strategies	Andres Duarte-Rojo	
8:50-9:00	MHE testing in an ideal situation	Manuel Romero-Gomez	
9:00-9:10	Ethical / legal issues	Kevin Mullen	
9:10-9:25	Young Investigator selected from the submitted abstracts		
9:25-9:40	Young Investigator selected from the submitted abstracts		
9:40-10:00	Panel Discussion		

08:00-10:00

SESSION 5: WORKSHOP 2 (BASIC): ANIMAL MODELS

Learning Objective: To review the animal models used to study hepatic encephalopathy

Chairs: Cristina Cudalbu and Roger Butterworth

Speakers

	Title of the Talk	Speaker	Institution
8:00-8:15	Acute liver failure (Type A hepatic encephalopathy)	Scott Nyberg	
8:15-8:30	Type B hepatic encephalopathy	Marc Oria	
8:30-8:45	Chronic liver disease(Type C hepatic encephalopathy)	Christopher Rose	
8:45-9:00	Acute on chronic liver failure	Natalia Arias	
9:00-9:15	Young Investigator selected from the submitted abstracts		
9:15-9:30	Young Investigator selected from the submitted abstracts		
9:30-10:00	Panel Discussion		

10:00-10:30

Refreshment Break

10:30-12:30 SESSION 6: HEPATIC ENCEPHALOPATHY IN SPECIAL SITUATIONS**Learning Objective:** To review the current classification of HE and also to find out whether further improvement/change is required?**Chairs:** Fin Larsen and Marsha Morgan**Speakers**

	Title of the Talk	Speaker	Institution
10:30-10:45	Epidemiology, types and diagnosis	Peter Jepsen	
10:45-11:00	Alcohol: Withdrawal / Intoxication / Wernicke's	Sandeep Grover	
11:00-11:15	Hepatic encephalopathy related to ACLF: Is it different?	Rajiv Jalan	
11:15-11:30	Pre/post transplant HE management	Simone Strasser	
11:30-11:40	Young Investigator selected from the submitted abstracts		
11:40-11:50	Young Investigator selected from the submitted abstracts		
11:50-12:15	Panel discussion		

12:15-13:00 Lunch**13:30-15:00 SESSION 7: ACUTE LIVER FAILURE****Learning Objective:** To review the pathogenesis and late outcome of ALF**Chairs:** Scott Nyberg and Yogesh Chawla**Speakers**

	Title of the Talk	Speaker	Institution
13:00-13:20	Neurological Monitoring in ALF	Banwari Agarwal	
13:20-13:40	Role of Ammonia, Inflammation and other factors in pathogenesis of brain edema	Subrat Acharya	
13:40-14:00	Neurological recovery after recovery from acute liver failure (both spontaneous or after liver transplantation): Is it complete?	Dominique Thabut	
14:00-14:15	Young Investigator selected from the submitted abstracts		
14:15-14:30	Young Investigator selected from the submitted abstracts		
	Discussion		

14:30-16:00 SESSION 8: MINIMAL HEPATIC ENCEPHALOPATHY: NEWER METHODS AND APPROACHES**Learning Objective:** Challenges in making the diagnosis of minimal HE**Chairs:** Gitte Dam and Subrat Acharya**Speakers**

	Title of the Talk	Speaker	Institution
14:30-14:45	Is 1 test better than 2?	Piero Amodio	
14:45-15:00	Non-specialized methods to screen MHE	Mette Lauridsen	
15:00-15:15	Critical flicker frequency	Gerald Kircheis	
15:15-15:30	Impact of co-morbid conditions (Dementia, diabetes, etc)	Karin Weissenborn	

15:30-15:45	Young Investigator selected from the submitted abstracts		
14:45:16:00	Young Investigator selected from the submitted abstracts		

16:00-16:30 Tea break

16:30-18:00 SESSION 9: NEW TECHNOLOGIES – NEW INSIGHTS

Learning Objective: This session will discuss the latest methodologies and techniques that can be used to examine HE and its related conditions. The focus should not necessarily be on the techniques themselves, but rather on the types of information that can be derived from them and how this may influence future treatment.

Chairs: **Boris Görg and Simon Taylor Robinson**

Speakers:

	Title of the Talk	Speaker	Institution
16:30-16:50	Genomics, proteomics and metabolomics	Mark McPhail	
16:50-17:10	Microbiome assessment	Vishal Patel	
17:10-17:30	Newer brain imaging techniques	Michael Sorensen	
17:30-17:45	Young Investigator selected from the submitted abstracts		
17:45-18:00	Young Investigator selected from the submitted abstracts		

18:00-19:00 Football Match

20:00 Dinner

ISHEN 2016
Day 3 [Treatment] March 11, 2017

08:00-10:00 **SESSION 10: WORKSHOP 3 (CLINICAL): THE GUT, LIVER AND BRAIN AXIS**

Learning Objective: This session will consider the relationship between the three organ systems; the known ammonia trafficking that occurs between them; and the role of gut glutaminase. Importantly, the session will explore the role of dysbiosis, translocation, priming of the brain and targeting these processes as potential current and future therapeutic targets.

Chairs: **Rajiv Jalan and Manuel Romero-Gomez**

Speakers

	Title of the Talk	Speaker	Institution
8:00-8:20	Gut microbiota in health + methods of detection	Rakesh Aggarwal	
8:20-8:40	Alterations in gut microbiota in cirrhosis of liver and hepatic encephalopathy	Jasmohan Bajaj	
8:40-9:00	Gut-liver axis and alcoholic liver disease	Gyongyi Szabo	
9:00-9:15	Young Investigator selected from the submitted abstracts	To be selected	
9:15-9:30	Young Investigator selected from the submitted abstracts	To be selected	
9:30-10:00	Panel discussion		

08:00-10:00 **SESSION 11: WORKSHOP 4 (BASIC): AMMONIA: MORE THAN JUST A NEUROTOXIN**

Learning Objective: This workshop will examine and discuss the evidence and mechanisms of toxic effect of ammonia other than neurotoxicity.

Chairs: **Christopher Rose and Raj Mookerjee**

Speakers

	Title of the Talk	Speaker	Institution
8:00-8:15	Muscle	S Dasarathy	
8:15-8:30	Liver, Lung, Heart,	Balasubramaniyan Vairappan	
8:30-8:45	Immune cells	Vishal Patel	
8:45-9:00	Implication for fatty liver progression	Karen Louise Thomsen	ISHEN Member
9:00-9:15	Young Investigator selected from the submitted abstracts	To be selected	
9:15-9:30	Young Investigator selected from the submitted abstracts	To be selected	
9:30-10:00	Panel discussion		

10:00-10:30 Refreshment Break

10:30-11:30 Design of therapeutic clinical trials in HE

Learning Objective: This section will elaborate on the selection of patients, standards of care and end-points for assessing the treatment.

Chairs: Piero Amodio and Kevin Mullen

Speakers

	Title of the Talk	Speaker	Institution
10:30-10:50	What are the clinical end points for HE/MHE clinical trials?	Lise-lotte Gluud	
10:50-11:10	How to design a multicenter clinical trial in HE?	Oliviero Riggio	
11:10-11:30	Regulatory issues in clinical trials in HE	Linda Grais	

11:30-12:30 Treatment: Special situations

LearningObjective: This section will elaborate on the treatment of minimal HE and ACLF and on the prevention of HE.

Chairs: Ramesh RoopRai and Mark Swain

Speakers

	Title of the Talk	Speaker	Institution
11:30-11:50	Minimal hepatic encephalopathy	Radha K. Dhiman	
11:50-12:10	Primary and secondary prophylaxis	Barjesh Sharma	
12:10-12:30	Acute on chronic liver failure		

12:30-13:30 Lunch

13:30-15:30 SESSION 12: TREATMENT: PHARMACOLOGICAL

LearningObjective: To review the pharmacological treatment of HE

Chairs: BarjeshSharma and OlivieroRiggio

Speakers

	Title of the Talk	Speaker	Institution
13:30-13:45	Lactulose	Vivek A Saraswat	
13:45-14:00	Rifaximin	Kevin Mullen	
14:00-14:15	BCAA	Gitte Dam	
14:15-14:30	Probiotics	Radha K Dhiman	

14:30-14:45	L-ornithine L-aspartate	Roger Butterworth	
14:45-15:00	Ornithine-Phenylacetate	Nathan Davies	
15:00-15:15	Young Investigator selected from the submitted abstracts	To be selected	
15:15-15:30	Young Investigator selected from the submitted abstracts	To be selected	
15:30-15:45	Discussion		

15:45-16:15 Tea break

16:15-18:00 SESSION 13: TREATMENTS 2: NONPHARMACOLOGICAL

Learning Objective: To review the non-pharmacological treatment of HE and liver failure

Chairs: **Shiv K. Sarin and Jasmohan Bajaj**

Speakers

	Title of the Talk	Speaker	Institution
16:15-16:35	Liver regeneration	Shiv K Sarin	
16:35-16:50	Exercise-What we have learnt from animal models	Chantal Bémeur	
16:50-17:05	Exercise-Clinical experience	Puneeta Tandon	
17:05-17:20	Nutrition	Manuela Merli _	
17:20-17:35	High volume plasma exchange / Albumin dialysis	Fin Larsen	
17:35-17:50	Young Investigator selected from the submitted abstracts	To be selected	
17:50-18:05	Young Investigator selected from the submitted abstracts	To be selected	

19:00 Gala Dinner and Prizes

Day 4: Departures in the morning